Syra Health Posts Second Straight Profitable Quarter, Revenue Up 23%
SYRA has more than doubled off its 52-week low of $0.052.
Summary
Syra Health reported Q2 2026 net income of $250,242 on revenue of $2.4 million, marking its second straight profitable quarter. Gross margin expanded to 44.5%, and the company reiterated its full-year profitability goal.
Key Events · Earnings and Guidance · SYRA
-
Second Consecutive Profitable Quarter
Net income of $250,242 in Q2 2026, compared to a net loss of $(63,596) in Q2 2025, marking the second straight quarter of profitability after the company's first-ever profitable quarter in Q1 2026.
-
Revenue Growth of 23%
Total revenue reached $2.4 million, up from $1.9 million in the prior-year period, driven by an 8% increase in population health solutions and an 87% surge in healthcare workforce revenue.
-
Record Gross Margin Expansion
Gross margin improved to 44.5% from 38.7% a year ago, the highest quarterly gross margin in company history, reflecting a favorable revenue mix and operating leverage.
-
Strong Balance Sheet
Cash and cash equivalents stood at $2.1 million as of June 30, 2026, with no long-term debt, and operating cash flow for the first six months was $643,183.
Analysis · SYRA · Trade & Services
Syra Health delivered its second consecutive profitable quarter, with net income of $250,242 versus a loss a year ago. Revenue grew 23% to $2.4 million, and gross margin hit a record 44.5%. The company has $2.1 million in cash and no long-term debt, and it reaffirmed its target for full-year profitability. For a micro-cap company that was unprofitable until recently, this sustained turnaround is a meaningful signal that the business model is gaining traction.
At the time of this filing, SYRA was trading at $0.66 on OTC in the Trade & Services sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $0.05 to $1.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.